Cite
Protocol for a double-blind, randomized controlled trial on the dose-related efficacy of omalizumab in multi-food oral immunotherapy.
MLA
Langlois, Alexandra, et al. “Protocol for a Double-Blind, Randomized Controlled Trial on the Dose-Related Efficacy of Omalizumab in Multi-Food Oral Immunotherapy.” Allergy, Asthma & Clinical Immunology, vol. 16, no. 1, Apr. 2020, pp. 1–16. EBSCOhost, https://doi.org/10.1186/s13223-020-00419-z.
APA
Langlois, A., Lavergne, M.-H., Leroux, H., Killer, K., Azzano, P., Paradis, L., Samaan, K., Lacombe-Barrios, J., Mâsse, B., Des Roches, A., & Bégin, P. (2020). Protocol for a double-blind, randomized controlled trial on the dose-related efficacy of omalizumab in multi-food oral immunotherapy. Allergy, Asthma & Clinical Immunology, 16(1), 1–16. https://doi.org/10.1186/s13223-020-00419-z
Chicago
Langlois, Alexandra, Marie-Hélène Lavergne, Hélène Leroux, Kerstin Killer, Pauline Azzano, Louis Paradis, Kathryn Samaan, et al. 2020. “Protocol for a Double-Blind, Randomized Controlled Trial on the Dose-Related Efficacy of Omalizumab in Multi-Food Oral Immunotherapy.” Allergy, Asthma & Clinical Immunology 16 (1): 1–16. doi:10.1186/s13223-020-00419-z.